At-Home Brain Stimulation Treatment Can Safely Ease Depression
By Dennis Thompson HealthDay Reporter
TUESDAY, Oct. 22, 2024 -- At-home brain stimulation therapy can safely and effectively treat severe to moderate depression, a new clinical trial shows.
Rates of treatment response and depression remission were three times higher in people receiving the noninvasive brain stimulation, researchers said.
“The study results bring promise that an innovative treatment modality may become available for patients suffering from mood disorders some time in the near future,” said co-lead researcher Dr. Jaire Soares, chair of psychiatry with the University of Texas McGovern Medical School.
For the study, 174 people diagnosed with depression were randomly assigned to receive or forego brain stimulation during a 10-week course of treatment.
Those receiving brain stimulation got five 30-minute sessions a week for the first three weeks, followed by three 30-minute sessions a week for the next seven weeks.
The therapy is called transcranial direct current stimulation (tDCS), in which a current of between 0.5 to 2 milliampere is applied to the scalp through two electrodes. This amount of electricity causes at most a slight tingling sensation along the scalp.
The stimulation was self-administered by patients in their own homes, researchers said.
About 45% of people receiving the stimulation wound up with their depression in remission, compared with 22% of the control group, researchers found.
“The burden of depression is mostly keenly felt by the 280 million people worldwide currently managing symptoms. While a combination of antidepressants and therapy generally proves to be effective for many people, medication can have side effects that some can find disruptive,” said senior researcher Dr. Cynthia Fu, a professor of affective neuroscience and psychotherapy at King’s College London.
“Our study has demonstrated that tDCS is a potential first-line option that could help those in need,” Fu added in a University of Texas news release.
The study was funded by Flow Neuroscience, the manufacturer of the stimulation device.
The study was published Oct. 21 in the journal Nature Medicine.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-23 06:00
Read more
- Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with Keytruda (pembrolizumab) After Neoadjuvant Keytruda and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
- Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
- FDA Approves Orlynvah (sulopenem etzadroxil and probenecid) for the Treatment of Uncomplicated Urinary Tract Infections
- Ordinal Score Predicts Freedom From Epilepsy One Year After Surgery
- Vasomotor Symptoms During Menopause May Up Risk for Type 2 Diabetes
- Having a Preemie Baby Can Harm Job Prospects, Income
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions